ArticleJournal of the American Heart Association2023
Complications and Outcomes of Impella Treatment in Cardiogenic Shock Patients With and Without Acute Myocardial Infarction.
Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024.Cardiovascular intervention and therapeutics · 2024Guideline
- Limiting collateral damage: Nosocomial infections in patients with temporary mechanical circulatory support.JHLT open · 2026Article
- UK multisociety consensus statement on the emergency management and resuscitation of patients with left-sided Impella support.Heart (British Cardiac Society) · 2026Article
- Comparative Outcomes of Direct Impella Use vs. Intra-Aortic Balloon Pump (IABP)-to- Impella Escalation Strategy in Cardiogenic Shock: Insights from the National Inpatient Sample.Research square · 2026Article
- Incidence and Management of Access Site Infection Following Trans-Axillary Implant of a Microaxial Left Ventricular Assist Device.Artificial organs · 2026Article
- Toward standardized guidelines for distal perfusion cannulae in V-A ECMO and ECPELLA: timing, sizing, monitoring, and management.The journal of extra-corporeal technology · 2026Article
- CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026.Cardiovascular intervention and therapeutics · 2026Article
- Patterns of temporary mechanical circulatory support, escalation, de-escalation and outcomes in cardiogenic shock.Frontiers in cardiovascular medicine · 2026Article
- Extracorporeal Membrane Oxygenation in Acute Cardiovascular Care.Circulation reports · 2025Review
- The Role of Impella in Cardiogenic Shock in the Post-DanGer Shock Era.Biomedicines · 2025Review
- Impact of Baseline Cardiogenic Shock Severity on Outcomes in Patients Treated With Impella Device.Journal of the American Heart Association · 2025Observational
- Efficacy of a 16 Fr sheath strategy during Impella support to reduce access site bleeding in patients with cardiogenic shock.Heart and vessels · 2025Article
- Temporary Extracorporeal Bypass System for Prevention of Acute Limb Ischemia From Percutaneous Ventricular Assist Device.JACC. Case reports · 2025Article
- Complications Leading to Death in Patients Supported by the Impella 5.5: Analysis From the FDA MAUDE Database.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Article
- Hemodynamic improvement with Impella RP in acute massive pulmonary embolism: a narrative review of cardiovascular outcomes and pulmonary catheter pressure assessment.Annals of medicine and surgery (2012) · 2025Review
- A Canadian Experience With a Percutaneous Microaxial Ventricular Assist Device in Children With Cardiogenic Shock.CJC pediatric and congenital heart disease · 2025Article
- Combined Risk Stratification With Patient Characteristics and Biomarkers in Patients Treated With the Impella for Cardiogenic Shock.Journal of the American Heart Association · 2025Article
- Patient-specific Predictors of Haemolysis with Percutaneous Ventricular Assist Devices.Cardiac failure review · 2025Article
- Infections in Patients with Mechanical Circulatory Support.Infectious disease clinics of North America · 2024Review
- Intra-aortic balloon pump is associated with the lowest whereas Impella with the highest inpatient mortality and complications regardless of severity or hospital types.Cardiovascular intervention and therapeutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background In patients with cardiogenic shock (CS), acute myocardial infarction (AMI) is the most common cause, and a percutaneous microaxial ventricular assist device (Impella, Abiomed, Danvers, MA) is a choice for temporary mechanical circulatory support. However, data are limited on complications and outcomes of Impella treatment in patients with CS with and without AMI. Methods and Results Using nationwide prospective registry data in Japan, we included a total of 2047 patients with CS in whom the Impella devices were successfully placed between February 2020 and December 2021. Patients were divided into 2 groups according to the primary indication for the Impella use: AMI versus non-AMI. The primary end point was a composite of in-hospital all-cause death and major complications. Of the 2047 patients, the Impella was indicated for AMI in 1337 (65.3%). In the group without AMI, myocarditis was the leading cause of CS. Patients with AMI-CS were older and more likely to have cardiovascular risk factors than those with non-AMI-CS. The rates of in-hospital mortality (46.0% versus 43.9%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.